The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

In terms of valuation, Summit Therapeutics Inc’s market capitalization stands at $15.87 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Robert Duggan, Co-CEO & Executive Chairman of the company, who spent a ...

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net ...

Under the leadership of Summit Therapeutics Co-CEO Maky Zanganeh, shares have risen 17-fold, bollstered by positive data on its leading drug candidate. In the ultra-competitive world of cancer ...

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, will present its ONCO Prime ...

Bob Duggan & Maky Zanganeh, Summit Therapeutics co-CEOs, join 'Fast Money' to talk its lung cancer drug and continuing ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...